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Abstract 
The development of targeted next-generation sequencing (NGS) applications now 
promises a clinically viable option for the diagnosis of rare disorders. This approach 
is proving to have significant utility where standardized testing has failed to identify 
the underlying molecular basis of disease. We have developed a unique targeted 
NGS panel for the systematic sequence-based analysis of atypical iron disorders. 
We report the analysis of 39 genes associated with iron regulation in 8 cases of 
atypical iron dysregulation, in which we identified the definitive causative mutation in 
5 cases, and a possible causative mutation in a sixth. We further provide a molecular 
and cellular characterization study of one of these mutations (TFR2, p.I529N) in a 
familial case as proof-of-principle. Cellular analysis of the mutant protein indicates 
that this amino acid substitution affects the localization of the protein resulting in its 
retention in the endoplasmic reticulum and thus failure to function at the cell surface. 
Our unique NGS panel presents a rapid and cost-efficient approach to identifying the 
underlying genetic cause in cases of atypical iron homeostasis disorders. 
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Introduction 
The advent of next-generation sequencing (NGS) offers the ability to sequence large 
amounts of DNA rapidly and has promised the ability to overcome the restriction of 
single gene analysis; its practicality for clinical use has been limited until recently by 
the cost and complex post-sequencing interpretation. A more recent and strategic 
approach, however, has been the development of targeted gene panels and scalable 
NGS systems, which leverage the power and economics of NGS [1]. 
 
Atypical iron disorders represent a spectrum of iron dysregulation ranging from 
juvenile onset iron overload through to iron-refractory iron-deficiency anaemia 
(IRIDA). The most common form of primary iron overload disease, HFE-related 
hereditary hemochromatosis (HFE-HH), accounts for anywhere between 60-95% of 
cases of iron overload in European populations [2]. However, a significant and 
growing number of atypical iron disorders are being identified, particularly within non-
European populations [2]. These cases have historically proven difficult to genetically 
diagnose, as beyond genotyping for the common HFE mutations, there is no 
standardized process for the further investigation of the underlying genetic cause. 
 
Iron homeostasis is regulated through the hepcidin/ferroportin axis. Hepcidin, a liver-
expressed peptide hormone, regulates the protein levels of the iron exporter 
ferroportin. The regulation of hepcidin itself is significantly more complex. The 
primary iron sensing and iron responsive regulation of hepcidin occurs through the 
bone morphogenetic protein (BMP)/ mothers against decapentaplegic homolog 
(SMAD) signaling pathway, which can be augmented by innate immune responses 
to infection and inflammation, hypoxia and oxidative stress leading to changes in 
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hepcidin expression, along with sex hormones also affecting hepcidin regulation [for 
review see 3].  Mutations in the genes involved in any of these systems thus have 
the potential to influence iron homeostasis, and ultimately result in iron 
dysregulation. 
 
Whilst the treatment of the more common forms of iron overload are similar, specific 
diagnosis remains important in atypical cases in which alteration in treatment and/or 
monitoring are recommended. An example of this is classical ferroportin disease 
where cellular iron export capacity is reduced, inhibiting both iron recycling through 
the reticuloendothelial system and the release of iron from tissues. In this 
pathophysiological setting, phlebotomy can be poorly tolerated by patients due to the 
reduced iron available for erythropoiesis and often results in anemia. Consequently, 
the treatment regimen for classical ferroportin disease differs from other forms of iron 
overload, and increased monitoring of hemoglobin levels is required [reviewed in 2]. 
Similarly, treatment of IRIDA due to mutations in the TMPRSS6 gene via oral iron 
supplementation provides no clinical benefit to the patient, with iron supplementation 
via parenteral routes required [4]. 
  
Here, we report on the first application of an iron-specific gene panel targeted NGS 
approach to the genetic analysis of 8 cases of atypical iron disorders. We report the 
identification of novel or rare non-synonymous deleterious mutations in 6 subjects 
with iron overload, and provide the biological characterization of a novel causative 
mutation in the TFR2 gene as proof-of- principle. 
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Materials and Methods 
Patient consent 
This study was approved by and performed in accordance with the ethical standards 
of the QIMR Berghofer Human Research Ethics Committee and with the Helsinki 
Declaration of 1975, as revised in 1983. Informed and written consent was obtained 
for the studies described in this report. 
 
Patients 
Included cases had demonstrated persistently abnormal iron indices which were 
significantly elevated (serum Ferritin >1000 µg/L for males and >700 for females), 
and were negative for p.C282Y homozygosity. 
 
Next-Generation Sequencing 
Gene panel 
We report on a panel of 39 genes either currently associated with genetic iron 
overload or anemia, or for which evidence from animal models or in vitro 
experiments demonstrates a contribution to iron homeostasis. The whole transcripts 
of these genes, and promoter regions from 11 of these, were then used to generate 
a custom “AmpliSeq” panel (Life Technologies, Mulgrave, Victoria, Australia). The 
genes sequenced for this report are listed in Table 1. 
 
Library preparation and Sequencing 
gDNA was isolated from fresh EDTA blood and the sequencing library generated 
from 10 ng gDNA using “Ion Ampliseq Library Kit 2.0” and Ion PGM™ Template OT2 
200 Kit (Life Technologies) as per manufacturer’s protocol. The library was then 
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sequenced using “Ion PGM 200 V2 sequencing kit” chemistry on an “Ion PGM 316 
chip” on an Ion Torrent PGM (Life Technologies). 
 
Analysis 
Post run QC/QA filtering was performed using Torrent Suit (v3.6; Life Technologies), 
and sequences aligned to the human genome version 19 (HG19) using T-MAP 
(version 3.6.58977). Variants were called using the Torrent Variant Caller (version 
3.6.59049, with Germ Line - Low Stringency configuration), and annotated using 
wANNOVAR [5]. The potential functional impact of identified variants was assessed 
using the predictive algorithms available in wANNOVAR. Finally potentially causative 
mutations identified as being novel or rare and with some predictive indicators, were 
confirmed by Sanger sequencing. 
 
Generation of mutant TFR2 constructs 
The wild-type FLAG-tagged TFR2 construct was a generous gift from Prof Kawabata 
[6].  Site-directed mutagenesis was then used to introduce the TFR2 disease-
causing mutations p.M172K and p.I529N as described previously [7]  using mutation-
specific primers (p.M172K F GCTCGGCCGGGAAGGCCGCTCTGAC, p.M172K R 
GTCAGAGCGGCCTTCCCGGCCGAGC, p.I529N F 
CCTTCTGACAAGTCTCAATGAGAGTGTCCTGAAGC, p.I529N R 
GCTTCAGGACACTCTCATTGAGACTTGTCAGAAGG).  Presence of mutations was 
confirmed by DNA Sanger Sequencing. 
 
Transfections 
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HepG2/C3A (CRL-10741, American Type Culture Collection, Manassas, VA) cells 
were transiently transfected with TFR2 constructs by reverse transfection in 
collagen-coated 6 well plates using Viafect (Promega, Alexandria, NSW, Australia) 
according to the manufacturer’s instructions. 
 
Immunofluorescence studies 
Transfected cells were grown on collagen-coated glass coverslips for 24hrs. For 
permeabilized labeling, cells were treated as previously described [8], using the 
primary antibodies, anti-FLAG at 1:500 (M2, Sigma-Aldrich, Castle Hill, NSW, 
Australia), anti-calnexin at 1:100 [gift from Dr. David J. McKean, and previously 
characterized in 9], or anti-TFR2 at 1:100 [previously characterised in 7]. For 
surface-specific labeling, cells were treated as previously described [7], using anti-
FLAG at 1:500 and anti-TFR2. Coverslips were mounted using Prolong Gold Anti-
fade mounting media with DAPI (Invitrogen, Mount Waverley, Victoria, Australia). 
Fluorescent images were viewed and captured at 63x magnification using a Zeiss 
AxioScope NLO-780 confocal microscope. 
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Case Report 
Patient sequencing 
We report here on the sequencing output from 8 patients with significant and well- 
characterized iron dysregulation. Patient details are shown in Table 2; all were 
Australian residents of differing ethnicities. 8 different novel or rare (MAF<0.001) 
SNPs were identified, accounting for potentially causative mutations in 6 out of 8 
cases. Identified novel and rare variants are reported in Table 2. 
 
Two of the 8 cases (Table 2, cases 1 and 2) are patients for which we have 
previously identified and published the causative mutation [8, 10], and which thus 
served as validation controls for the panel. A third case (case 3) has previously also 
been published [11], however the original identified mutation whilst known to cause 
iron overload, did not fully explain the severity of the disease. In this case, NGS 
sequencing identified a novel heterozygous mutation in the HFE gene leading to a 
p.T17I substitution in addition to the previously identified p.H63D mutation. The 
proband’s mother was also heterozygous for p.H63D, but did not carry the T17I 
mutation suggesting the proband is likely HFE p.T17I/p.H63D compound 
heterozygous. Compound heterozygosity for p.H63D and p.C282Y has been linked 
to  iron overload [12]; this new finding may explain the increased severity seen in his 
case. Cases 4 to 8 have not been previously reported and sequencing of these 
patients identified mutations in cases 4 (HFE2, p.G320V), 5 (HEPHL1, p.D136V) and 
6 (TFR2, p.I529N). In cases 7 and 8, whilst several common non-synonymous SNPs 
were present, these were not considered to be the likely cause of disease. 
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Case study 
A 56-year-old female (case 6) of Maltese origin presented with a history of 
phenotypically diagnosed iron overload with an elevated serum ferritin (SF) of 667 
µg/L and transferrin saturation (TS) of 85%. On follow-up at 2 months, SF was 780 
µg/L and TS 95%, with normal alanine aminotransferase (ALT = 27 IU/L, normal <55 
IU/L), aspartate aminotransferase (AST = 24 IU/L, normal 10-40 IU/L), and serum 
gamma-glutamyl transferase (GGT = 15 IU/L, normal 7-43 IU/L) levels.  
 
Targeted NGS identified 152 variants across the 39 genes and 11 promoters that 
comprise the panel, when aligned to HG19. The proband was reported to be 
negative on her HFE gene test, which was confirmed by our sequencing. Identified 
variants were then filtered based on their minor allele frequency (MAF) in the 1000 
Genomes, Exome Sequencing Project 6500, and Exome Aggregation Consortium 
databases. Variants were then assessed for effects on protein coding; a single 
homozygous novel nucleotide point mutation c.1586T>A (NM_003227.3; 
Chr7:100225549) in the TFR2 gene which results in the amino acid substitution 
p.I529N (NP_003218.2) was identified (Fig. 1). This DNA change was confirmed by 
Sanger sequencing. The potential functional impact of this mutation was assessed 
through wANNOVAR [5] with SIFT (score, 0: prediction Deleterious), Pholyphen2-
HVAR (0.961: Deleterious), LRT (0: Deleterious), MutationTaster (1: Deleterious), 
CADD (score=15.07), and Grantham (score=194) scores predicting a deleterious 
consequence from this substitution. 
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The proband’s 55 year-old sister also presented with a SF of 475 µg/L and TS of 
91%. Sanger sequencing of the sister specifically for the p.I529N variant identified 
her to also be homozygous for the variant. 
 
To assess the functional impact of this mutation, and the likelihood that it is the 
underlying cause of iron overload in the patient, functional characterization was 
performed. As TFR2 functions at the cell surface, we initially assessed the cellular 
localization of the p.I529N, along with a previously reported loss-of-function mutation 
p.M172K [13] . Cells were transiently transfected with expression constructs 
encoding either the wild-type, p.M172K or p.I529N TFR2 protein with a FLAG-tag at 
the amino-terminus, and localization assessed by immunofluorescence (IF) 
microscopy. As the amino-terminus of the TFR2 protein is located intracellularly, we 
used our previously described antibody [7] against the extra-cellular domain of the 
TFR2 protein to assess cell surface-specific localization of the various TFR2 
constructs (Fig 2A). As expected, wild-type TFR2 efficiently localized to the cell 
surface, however neither the p.M172K or p.I529N mutants were detectable. To 
identify the cellular localization of the mutant TFR2 proteins, intracellular IF was 
performed. This showed significant protein expression of the mutants, both of which 
were retained intracellularly and co-localized with the endoplasmic reticulum (ER) 
marker calnexin (Fig. 2B). No wild-type protein was found to co-localize with 
calnexin, demonstrating specific retention of the mutant proteins in the ER. The 
failure of mutant TFR2 to localize correctly to the cell surface underlies its inability to 
act in the regulation of hepcidin, and is thus the likely cause of the patient’s iron 
overload disorder. 
  
  
 
12 
Discussion 
We have successfully applied our NGS approach, utilizing a novel targeted gene 
panel, to identify the underlying genetic cause in 6 out of 8 cases of atypical iron 
overload where standard testing had been unable to provide a genetic diagnosis. We 
report the identification of a novel p.I529N mutation in TFR2 which results in a failure 
in trafficking of the protein to the cell surface, similar to that seen for the p.M172K 
mutant. In this case study we have demonstrated the utility and viability of targeted 
NGS for identifying causative mutations. We believe that our gene panel and this 
novel approach will provide an important resource to the scientific and clinical 
community for identifying the genetic basis of atypical iron disorders. 
 
TFR2 is a key molecule involved in the regulation of iron homeostasis. It plays a 
critical role in iron sensing through to the eventual regulation of hepcidin. TFR2 
mutations have been shown to cause type 3 haemochromatosis, a form which has 
been reported to have an earlier onset and higher levels of iron than the more 
common HFE-HH [14]. In this study we used the p.M172K mutation [previously 
reported in 13] as a positive control for the cellular characterization of our novel 
p.I529N mutant. While the clinical phenotype of the p.M172K mutant has been 
described and the M167K mouse equivalent studied [7, 15], this is the first report of 
the underlying cellular defect in a human system. It is of note that the family carrying 
the p.M172K mutation included an affected female of slightly younger age than the 
current reported cases of p.I529N. This is of interest because the iron indices of the 
p.M172K female patient are similar to our p.I529N case study, with SF of 737 µg/L 
(current case 780 µg/L) and TS of 100% (current case 95%) in the presence of 
normal liver enzymes [13].  
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A challenge for the development of new diagnostic technologies for iron 
dysregulation is the high frequency of the HFE p.C282Y mutation in the European 
population which accounts for around 60-95% of iron overload cases, and for which 
the economical and rapid HFE gene test is widely available. This ease of genetic 
diagnosis is not applicable to cases with atypical iron disorders, where a combination 
of high cost and non-standardized methodologies is likely resulting in a significant 
number of suspected cases remaining genetically undiagnosed. 
 
The current approach to the genetic diagnosis of atypical iron disorders involves 
Sanger sequencing of the coding region of genes known to be involved in HH or 
IRIDA. The selection of which genes to analyse is usually based on the available 
clinical data, however, clinical presentation often appears similar across most of the 
current clinically associated genes [reviewed in 2]. This process is slow, iterative, 
costly, and in many cases still fails to identify the underlying genetic cause. Recent 
developments in NGS now allow its utilization in a practical, manageable, and cost-
efficient manner, and have allowed our group to establish a platform for sequencing 
39 iron regulatory genes in parallel for a cost comparable to that of sequencing a 
single gene using the Sanger approach. 
 
In conclusion, we present the first use of an iron homeostasis-specific targeted gene 
panel and NGS for the diagnosis of patients with atypical iron disorders, and report a 
case study demonstrating the utility of this approach. We have identified non-
synonymous deleterious mutations in 6 patient samples, and biologically 
characterized a novel mutation in the TFR2 gene identified in a familial case of iron 
overload, demonstrating the utility of the targeted NGS approach. The findings of this 
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study demonstrate the use of targeted NGS as an efficient and effective method for 
the diagnosis of atypical iron disorders. 
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Table 1: Genes and promoter regions sequenced 
Gene Name Short name (AKA) Function in Iron Homeostasis 
Hepcidin HAMP Master regulator 
HFE HFE Mutated in HH / Iron sensing? 
Transferrin receptor 2 TFR2 Mutated in HH / Iron sensing? 
aconitase 1, soluble ACO1 (IRP1) Iron sensing 
Iron-responsive element binding protein 2 IREB2 (IRP2) Iron sensing 
Hemochromatosis type 2 (juvenile)  HFE2 (HJV) BMP/SMAD Hepcidin regulation 
Transmembrane protease, serine 6 TMPRSS6 (MT2) BMP/SMAD Hepcidin regulation 
Bone morphogenetic protein 6 BMP6 BMP/SMAD Hepcidin regulation 
Activin A receptor, type IIA ACVR2A BMP/SMAD Hepcidin regulation 
Activin A receptor, type I ACVR1 (ALK2) BMP/SMAD Hepcidin regulation 
Bone morphogenetic protein receptor, type IA BMPR1A (ALK3) BMP/SMAD Hepcidin regulation 
SMAD family member 1 SMAD1 BMP/SMAD Hepcidin regulation 
SMAD family member 4 SMAD4 BMP/SMAD Hepcidin regulation 
SMAD family member 5 SMAD5 BMP/SMAD Hepcidin regulation 
SMAD family member 6 SMAD6 BMP/SMAD Hepcidin regulation 
SMAD family member 7  SMAD7 BMP/SMAD Hepcidin regulation 
SMAD family member 9 SMAD9 BMP/SMAD Hepcidin regulation 
Growth differentiation factor 15  GDF15 (MIC1) Hepcidin regulation 
Twisted gastrulation homolog 1 (Drosophila)  TWSG1 Hepcidin regulation 
Nuclear factor (erythroid-derived 2)-like 2 NFE2L2 Transcription factor 
Beta-2-microglobulin B2M Chaperone/HFE interaction 
Ferritin, light polypeptide  FTL Iron storage 
Ferritin, heavy polypeptide 1 FTH1 Iron storage 
Transferrin TF Iron transport 
Solute carrier family 40 (iron-regulated transporter), 
member 1  SLC40A1 (FPN) Iron export 
Transferrin receptor (p90, CD71) TFRC (TFR1) Iron import 
Solute carrier family 11 (proton-coupled divalent metal 
ion transporters), member 2  SLC11A2 (DMT-1) Iron import/export 
Solute carrier family 11 (proton-coupled divalent metal 
ion transporters), member 1 
SLC11A1 
(NRAMP) Metal ion transporter 
Solute carrier family 39 (zinc transporter), member 14  SLC39A14 (ZIP14) Zinc/iron transporter 
Ceruloplasmin (ferroxidase) CP Ferroxidase 
Amyloid beta (A4) precursor protein  APP Ferroxidase 
Hephaestin  HEPH Ferroxidase 
Hephaestin-like 1 HEPHL1 Ferroxidase 
Cytochrome b reductase 1  CYBRD1 (DCYTB) Ferric reductase 
Nedd4 family interacting protein 1 NDFIP1 Trafficking  
Nedd4 family interacting protein 2  NDFIP2 Trafficking 
Hypoxia inducible factor 1, alpha subunit (basic helix-
loop-helix transcription factor)  HIF1α Hypoxia/oxidative stress 
Endothelial PAS domain protein 1  EPAS1 (HIF2α) Hypoxia/oxidative stress 
Heme oxygenase (decycling) 1 HMOX1 Hypoxia/oxidative stress 
  
Promoter size Genomic region 
Promoter region of HFE -1485 chr6:26086024-26087509 
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Promoter region of hepcidin -2255 chr19:35771155-35773410 
Promoter region of hemochromatosis type 2 (juvenile)  -1000 chr1:145412191-145413191 
Promoter region of solute carrier family 40 (iron-
regulated transporter), member 1  -1681 chr2:190445537-190447218 
Promoter region of ferritin, light polypeptide  -1350 chr19:49467216-49468566 
Promoter region of ferritin, heavy polypeptide 1 -1000 chr11:61735132-61736132 
Promoter region of bone morphogenetic protein 6 -1000 chr6:7726011-7727011 
Promoter region of transmembrane protease, serine 6 -1000 chr22:37499693-37500693 
Promoter region of transferrin receptor (p90, CD71) -1000 chr3:195809032-195810032 
Promoter region of transferrin receptor 2 -1000 chr7:100239173-100240173 
Promoter region of transferrin -1700 chr3:133463277-133464977 
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Table 2: Clinical details of subjects and identified mutations 
 
Gender 
Age at 
diagnosis 
Ethnicity 
Transferrin 
Saturation 
Serum 
Ferritin 
Gene Change Zygosity Study 
1 M 86 Vietnamese 32 % 1530 SLC40A1 G80S Het [8] 
2 F 18 
European 
(undefined) 
91 % 2600 HFE2 
C80R Het 
[10] 
R326X Het 
3 M 32 
European 
(undefined) 
99 % 10510 
SLC40A1 N144D Het [11] 
HFE 
T17I Het This study 
H63D Het [11] 
4 M 37 Slavic 103 % 6400 HFE2 G320V Homo This study 
5 M 76 Vietnamese 27 % 754 HEPHL1 D136V Het This study 
6 F 55 Maltese 95 % 780 TFR2 I529N Homo This study 
7 F 60 
European 
(undefined) 
52 % 2508 - - - This study 
8 F 33 
Northern 
European 
55 % 1677 - - - This study 
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Figure Legends 
Fig 1. Identification of the c.1586T>A in the TFR2 gene of case 6 resulting in a 
p.I529N amino acid substitution. (A) Visualization of the NGS alignment to the 
positive strand of chromosome 7, and identification of the single nucleotide mutation 
of A to T at position 100225549 (HG19) where TFR2 is transcribed from the negative 
strand and represents the c.1586T>A change in the TFR2 transcript (NM_003227.3). 
The consensus sequence and associated translation of the TFR2 encoding negative 
strand shows Asparagine (N) at amino acid 529 while the reference sequence 
encodes for Isoleucine (I). (B) Matching chromatogram from Sanger DNA 
sequencing validating the single base mutation. 
 
Fig 2. The p.I529N and p.M172K mutations cause retention of the TFR2 protein 
in the endoplasmic reticulum. (A) Surface specific immunofluorescence of 
HepG2/C3A cells transfected with wild-type (WT), p.M172K, and p.I529N TFR2 
constructs. TFR1 provides a positive cell-surface marker in all cells. (B) Co-staining 
of WT, p.M172K, and p.I529N TFR2 with the endoplasmic reticulum marker calnexin. 
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